

# Lanadelumab for preventing recurrent attacks of hereditary angioedema

Information for the public

Published: 16 October 2019

[www.nice.org.uk](http://www.nice.org.uk)

Lanadelumab (Takhzyro) is available on the NHS as a possible treatment for preventing recurrent attacks of hereditary angioedema in people aged 12 and older if:

- they have 2 or more clinically significant attacks every week over 8 weeks, despite having oral preventative therapy or they cannot have oral therapy
- the lowest dosing frequency of lanadelumab is used when the condition is in a stable, attack-free phase.

If you are not eligible for lanadelumab but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS website](#) may be a good place to find out more.

This organisation can give you advice and support:

- [HAE UK](#), 07975 611787

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3565-9